Nagoya Firm Discovers A System To Deliver Drugs Into Brain
This article was originally published in PharmAsia News
Executive Summary
Nagoya-based Tissue Targeting Japan Inc. has developed the T2J peptide, a synthetic molecule that is able to permeate the blood-brain barrier and deliver drugs and materials directly inside human brains. Until now, the blood-brain barrier has blocked viruses and toxins as well as drugs from entering the brain. The T2J research team discovered that the microglial cell, a certain kind of glial cell, which accounts for 90 percent of brain cells, has the ability to permeate the brain blood barrier. Modeled after the microglial cell's movement pattern inside the brain, the T2J peptide can deliver chemicals directly to the brain. Tissue Targeting Japan will strengthen joint research with pharmaceutical companies and expects to launch a new drug using the peptide in 2015. (Click here for more-Japanese language
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.